When combined, patients may experience: Excessive appetite suppression , leading to inadequate caloric intake Unintended weight loss beyond therapeutic targets Nutritional deficiencies if dietary intake becomes severely restricted Difficulty maintaining energy for daily activities Hypoglycemia risk in patients also taking insulin or sulfonylureas, due to reduced food intake Gastrointestinal effects may also be compounded
longevity-
In the Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes published in 2024, it was recommended to start GLP-1 RA sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with T2DM and ASCVD, while also commenting upon noted benefit in specifically HFpEF as well [53]
Clinicians and patients alike should focus on what is firmly supported by evidence while maintaining healthy skepticism toward uses that have not yet been proved
But in my opinion, that study was not an appropriate control group because they were matching sweet taste between the sucralose plus carbohydrate group and the carbohydrate group, because I think their primary measure was actually, like, sweet tastes in the brain, looking at that
The hyperinsulinemic euglycemic clamp technique is the gold standard for measuring insulin sensitivity